N/A
Completed N=42
Pharmaco-epidemiological Description of the Population Treated With Aptivus Under Market Conditions, Safety & Efficacy
Source: ClinicalTrials.gov NCT00615290 ↗Enrolled (actual)
42
Serious AEs
7.1%
Results posted
Feb 2010
Primary outcomePrimary: Number of Patients With a Viral Load< 50 Copies/mL and a Gain in CD4 Higher Than 100 Cells/mm3 — 8 participants
Summary
To obtain information on clinical practices for patients treated by Aptivus in real life
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Patients With a Viral Load< 50 Copies/mL and a Gain in CD4 Higher Than 100 Cells/mm3 |
8 | — |
| SECONDARY Evaluation of Early Virological Response |
20 | — |
| SECONDARY Viral Load Response at 1 Month |
71.5 | — |
| SECONDARY CD4 Count at 1 Month |
349.0 | — |
| SECONDARY Evaluation of Intermediate Virological Response, Viral Load < 400 Copies/mL |
28 | — |
| SECONDARY Evaluation of Intermediate Virological Response, Viral Load < 50 Copies/mL |
24 | — |
| SECONDARY Viral Load Response at 3 Months |
49 | — |
| SECONDARY CD4 Count at 3 Months |
322.5 | — |
| SECONDARY Patient Self Perception of the New Treatment |
59; 76; 74 | — |
Eligibility Criteria
Inclusion Criteria
- HIV positive patients for whom Aptivus treatment is initiated by their physician
- Aptivus SCP respect
Exclusion Criteria
None if the inclusion criteria are respected: observational study
Data sourced from ClinicalTrials.gov (NCT00615290). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.